Plain language summary of the TOPAZ-1 study: durvalumab and chemotherapy for advanced biliary tract cancer

Do Youn Oh; Aiwu Ruth He; Shukui Qin; Li Tzong Chen; Takuji Okusaka; Arndt Vogel; Jin Won Kim; Thatthan Suksombooncharoen; Myung Ah Lee; Masayuki Kitano; Howard Burris; Mohamed Bouattour; Suebpong Tanasanvimon; Mairéad G. McNamara; Renata Zaucha; Antonio Avallone; Benjamin Tan; Juan Cundom; Choong Kun Lee; Hidenori Takahashi; Masafumi Ikeda; Jen Shi Chen; Julie Wang; Mallory Makowsky; Nana Rokutanda; Magdalena Żotkiewicz; John F. Kurland; Gordon Cohen; Juan W. Valle

doi:10.2217/fon-2023-0468

Plain language summary of the TOPAZ-1 study: durvalumab and chemotherapy for advanced biliary tract cancer

Do Youn Oh, Aiwu Ruth He, Shukui Qin, Li Tzong Chen, Takuji Okusaka, Arndt Vogel, Jin Won Kim, Thatthan Suksombooncharoen, Myung Ah Lee, Masayuki Kitano, Howard Burris, Mohamed Bouattour, Suebpong Tanasanvimon, Mairéad G. McNamara, Renata Zaucha, Antonio Avallone, Benjamin Tan, Juan Cundom, Choong Kun Lee, Hidenori TakahashiMasafumi Ikeda, Jen Shi Chen, Julie Wang, Mallory Makowsky, Nana Rokutanda, Magdalena Żotkiewicz, John F. Kurland, Gordon Cohen, Juan W. Valle

Research output: Contribution to journal › Review article › peer-review

3 Scopus citations

Abstract

This is a summary describing the results of a Phase III study called TOPAZ-1. The study looked at treatment with durvalumab (a type of immunotherapy) and chemotherapy to treat participants with advanced biliary tract cancer (BTC). Advanced BTC is usually diagnosed at late stages of disease, when it cannot be cured by surgery. This study included participants with advanced BTC who had not received previous treatment, or had their cancer come back at least 6 months after receiving treatment or surgery that aimed to cure their disease. Participants received treatment with durvalumab and chemotherapy or placebo and chemotherapy. The aim of this study was to find out if treatment with durvalumab and chemotherapy could increase the length of time that participants with advanced BTC lived, compared with placebo and chemotherapy.

Original language	English
Pages (from-to)	2277-2289
Number of pages	13
Journal	Future Oncology
Volume	19
Issue number	34
DOIs	https://doi.org/10.2217/fon-2023-0468
State	Published - 1 Nov 2023

Bibliographical note

Publisher Copyright:
© 2023 Future Medicine Ltd.. All rights reserved.

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.2217/fon-2023-0468

Cite this

Oh, D. Y., He, A. R., Qin, S., Chen, L. T., Okusaka, T., Vogel, A., Kim, J. W., Suksombooncharoen, T., Lee, M. A., Kitano, M., Burris, H., Bouattour, M., Tanasanvimon, S., McNamara, M. G., Zaucha, R., Avallone, A., Tan, B., Cundom, J., Lee, C. K., ... Valle, J. W. (2023). Plain language summary of the TOPAZ-1 study: durvalumab and chemotherapy for advanced biliary tract cancer. Future Oncology, 19(34), 2277-2289. https://doi.org/10.2217/fon-2023-0468

@article{d747c6072a2b459f9068b87f7d9c568d,

title = "Plain language summary of the TOPAZ-1 study: durvalumab and chemotherapy for advanced biliary tract cancer",

abstract = "This is a summary describing the results of a Phase III study called TOPAZ-1. The study looked at treatment with durvalumab (a type of immunotherapy) and chemotherapy to treat participants with advanced biliary tract cancer (BTC). Advanced BTC is usually diagnosed at late stages of disease, when it cannot be cured by surgery. This study included participants with advanced BTC who had not received previous treatment, or had their cancer come back at least 6 months after receiving treatment or surgery that aimed to cure their disease. Participants received treatment with durvalumab and chemotherapy or placebo and chemotherapy. The aim of this study was to find out if treatment with durvalumab and chemotherapy could increase the length of time that participants with advanced BTC lived, compared with placebo and chemotherapy.",

author = "Oh, {Do Youn} and He, {Aiwu Ruth} and Shukui Qin and Chen, {Li Tzong} and Takuji Okusaka and Arndt Vogel and Kim, {Jin Won} and Thatthan Suksombooncharoen and Lee, {Myung Ah} and Masayuki Kitano and Howard Burris and Mohamed Bouattour and Suebpong Tanasanvimon and McNamara, {Mair{\'e}ad G.} and Renata Zaucha and Antonio Avallone and Benjamin Tan and Juan Cundom and Lee, {Choong Kun} and Hidenori Takahashi and Masafumi Ikeda and Chen, {Jen Shi} and Julie Wang and Mallory Makowsky and Nana Rokutanda and Magdalena {\.Z}otkiewicz and Kurland, {John F.} and Gordon Cohen and Valle, {Juan W.}",

year = "2023",

month = nov,

day = "1",

doi = "10.2217/fon-2023-0468",

language = "English",

volume = "19",

pages = "2277--2289",

journal = "Future Oncology",

issn = "1479-6694",

publisher = "Future Medicine Ltd.",

number = "34",

}

Oh, DY, He, AR, Qin, S, Chen, LT, Okusaka, T, Vogel, A, Kim, JW, Suksombooncharoen, T, Lee, MA, Kitano, M, Burris, H, Bouattour, M, Tanasanvimon, S, McNamara, MG, Zaucha, R, Avallone, A, Tan, B, Cundom, J, Lee, CK, Takahashi, H, Ikeda, M, Chen, JS, Wang, J, Makowsky, M, Rokutanda, N, Żotkiewicz, M, Kurland, JF, Cohen, G & Valle, JW 2023, 'Plain language summary of the TOPAZ-1 study: durvalumab and chemotherapy for advanced biliary tract cancer', Future Oncology, vol. 19, no. 34, pp. 2277-2289. https://doi.org/10.2217/fon-2023-0468

TY - JOUR

T1 - Plain language summary of the TOPAZ-1 study

T2 - durvalumab and chemotherapy for advanced biliary tract cancer

AU - Oh, Do Youn

AU - He, Aiwu Ruth

AU - Qin, Shukui

AU - Chen, Li Tzong

AU - Okusaka, Takuji

AU - Vogel, Arndt

AU - Kim, Jin Won

AU - Suksombooncharoen, Thatthan

AU - Lee, Myung Ah

AU - Kitano, Masayuki

AU - Burris, Howard

AU - Bouattour, Mohamed

AU - Tanasanvimon, Suebpong

AU - McNamara, Mairéad G.

AU - Zaucha, Renata

AU - Avallone, Antonio

AU - Tan, Benjamin

AU - Cundom, Juan

AU - Lee, Choong Kun

AU - Takahashi, Hidenori

AU - Ikeda, Masafumi

AU - Chen, Jen Shi

AU - Wang, Julie

AU - Makowsky, Mallory

AU - Rokutanda, Nana

AU - Żotkiewicz, Magdalena

AU - Kurland, John F.

AU - Cohen, Gordon

AU - Valle, Juan W.

PY - 2023/11/1

Y1 - 2023/11/1

N2 - This is a summary describing the results of a Phase III study called TOPAZ-1. The study looked at treatment with durvalumab (a type of immunotherapy) and chemotherapy to treat participants with advanced biliary tract cancer (BTC). Advanced BTC is usually diagnosed at late stages of disease, when it cannot be cured by surgery. This study included participants with advanced BTC who had not received previous treatment, or had their cancer come back at least 6 months after receiving treatment or surgery that aimed to cure their disease. Participants received treatment with durvalumab and chemotherapy or placebo and chemotherapy. The aim of this study was to find out if treatment with durvalumab and chemotherapy could increase the length of time that participants with advanced BTC lived, compared with placebo and chemotherapy.

AB - This is a summary describing the results of a Phase III study called TOPAZ-1. The study looked at treatment with durvalumab (a type of immunotherapy) and chemotherapy to treat participants with advanced biliary tract cancer (BTC). Advanced BTC is usually diagnosed at late stages of disease, when it cannot be cured by surgery. This study included participants with advanced BTC who had not received previous treatment, or had their cancer come back at least 6 months after receiving treatment or surgery that aimed to cure their disease. Participants received treatment with durvalumab and chemotherapy or placebo and chemotherapy. The aim of this study was to find out if treatment with durvalumab and chemotherapy could increase the length of time that participants with advanced BTC lived, compared with placebo and chemotherapy.

UR - http://www.scopus.com/inward/record.url?scp=85177103205&partnerID=8YFLogxK

U2 - 10.2217/fon-2023-0468

DO - 10.2217/fon-2023-0468

M3 - Review article

C2 - 37746835

AN - SCOPUS:85177103205

SN - 1479-6694

VL - 19

SP - 2277

EP - 2289

JO - Future Oncology

JF - Future Oncology

IS - 34

ER -

Plain language summary of the TOPAZ-1 study: durvalumab and chemotherapy for advanced biliary tract cancer

Abstract

Bibliographical note

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this